Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

ATXS.US Logo

ATXS.US - Current Price

$12.72

Company Information

▼
Company Name
Astria Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04635X1028
CIK: 0001454789
CUSIP: 04635X102
Currency: USD
Full Time Employees: 78
Phone: 617 349 1971
Website: https://www.astriatx.com
Fiscal Year End: December
IPO Date: Jun 25, 2015
Description:

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Address:

22 Boston Wharf Road, Boston, MA, United States, 02210

Directors & Officers

▼
Name Title Year Born
Ms. Jill C. Milne Ph.D. Co-Founder, CEO, President & Director 1968
Mr. Benjamin S. Harshbarger J.D. Chief Legal Officer 1969
Dr. Christopher J. Morabito M.D. Chief Medical Officer 1970
Mr. Noah C. Clauser CPA CFO & Treasurer 1973
Ms. Keri McGrail Chief Human Resources Officer NA
Ms. Andrea L. Matthews Chief Business Officer 1982
Mr. Andrew A. Komjathy Chief Commercial Officer 1963
Mr. John Ruesch Senior Vice President of Pharmaceutical Sciences & Technical Operations NA
Ms. Rafif Dagher Senior VP and Head of Discovery, Nonclinical Development & Translational Research NA

Shares Statistics

▼
Shares Outstanding: 57.08M
Shares Float: 38.90M
% Insiders: 48.10%
% Institutions: 9,488.10%
Short % Float: 12.65%

Valuation Metrics

▼
Enterprise Value: $598.18M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $726.12M
EBITDA: $-32.38M
Book Value: $2.44
Earnings/Share: $-2.14
Profit Margin: 0.00%
Operating Margin: -4,830.60%
ROA (TTM): -26.94%
ROE (TTM): -43.15%
Revenue (TTM): $706.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Mar 31, 2026 0.00 -0.58 N/A 10,000.00%
Dec 31, 2025 0.00 -0.55 N/A 10,000.00%
Sep 30, 2025 -0.55 -0.42 N/A -3,095.24%
Jun 30, 2025 -0.57 -0.49 N/A -1,632.65%
Mar 31, 2025 -0.58 -0.48 N/A -2,146.60%
Dec 31, 2024 -0.44 -0.45 N/A 259.02%
Sep 30, 2024 -0.42 -0.42 N/A 0.00%
Jun 30, 2024 -0.43 -0.38 N/A -1,315.79%
Mar 31, 2024 -0.38 -0.36 N/A -555.56%
Dec 31, 2023 -0.94 -0.78 N/A -2,051.28%
Sep 30, 2023 -0.63 -0.49 N/A -2,857.14%
Jun 30, 2023 -0.45 -0.49 N/A 816.33%
Mar 31, 2023 -0.40 -0.55 N/A 2,727.27%
Dec 31, 2022 -0.72 -0.71 N/A -140.85%
Sep 30, 2022 -0.87 -0.92 N/A 543.48%
Jun 30, 2022 -0.86 -1.01 N/A 1,485.15%
Mar 31, 2022 -1.18 -0.73 N/A -6,164.38%
Dec 31, 2021 -11.00 -0.66 N/A -156,666.67%
Sep 30, 2021 -0.61 -0.77 N/A 2,077.92%
Jun 30, 2021 -1.26 -1.82 N/A 3,076.92%
Mar 31, 2021 -1.44 -0.92 N/A -5,652.17%
Dec 31, 2020 -2.64 -2.22 N/A -1,891.89%
Sep 30, 2020 -3.36 -3.06 N/A -980.39%
Jun 30, 2020 -3.18 -2.73 N/A -1,648.35%
Mar 31, 2020 -3.00 -2.46 N/A -2,195.12%
Dec 31, 2019 -3.30 -3.69 N/A 1,056.91%
Sep 30, 2019 -3.36 -3.82 N/A 1,204.19%
Jun 30, 2019 -3.72 -3.64 N/A -219.78%
Mar 31, 2019 -3.72 -4.17 N/A 1,079.14%
Dec 31, 2018 -7.20 -5.42 N/A -3,284.13%
Sep 30, 2018 -4.80 -8.08 N/A 4,059.41%
Jun 30, 2018 -12.00 -14.02 N/A 1,440.80%
Mar 31, 2018 -17.40 -12.04 N/A -4,451.83%
Dec 31, 2017 -14.40 -18.46 N/A 2,199.35%
Sep 30, 2017 -18.60 -20.05 N/A 723.19%
Jun 30, 2017 -19.20 -23.70 N/A 1,898.73%
Mar 31, 2017 -24.60 -27.15 N/A 939.23%
Dec 31, 2016 -28.20 -30.96 N/A 891.47%
Sep 30, 2016 -32.40 -39.00 N/A 1,692.31%
Jun 30, 2016 -36.60 -38.85 N/A 579.15%
Mar 31, 2016 -36.60 -38.55 N/A 505.84%
Dec 31, 2015 -37.80 -40.20 N/A 597.01%
Sep 30, 2015 -33.00 -38.40 N/A 1,406.25%
Jun 30, 2015 -8.07 -0.71 N/A -103,661.97%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $59.82M $N/A $342.36M $23.10M $319.26M
2023-12-31 $175.53M $N/A $254.67M $11.55M $243.12M
2022-12-31 $20.53M $N/A $230.63M $9.42M $221.22M
2021-12-31 $86.51M $N/A $127.51M $5.20M $122.31M
2020-12-31 $24.93M $N/A $47.46M $6.79M $40.67M
2019-12-31 $9.90M $N/A $41.78M $6.06M $35.72M
2018-12-31 $15.29M $N/A $39.17M $4.23M $34.94M
2017-12-31 $16.37M $N/A $17.90M $6.11M $11.79M
2016-12-31 $23.60M $N/A $40.21M $11.12M $29.09M
2015-12-31 $62.78M $N/A $64.22M $13.73M $50.49M
2014-12-31 $14.67M $N/A $15.96M $89.02M $-73.05M
2013-12-31 $30.47M $N/A $31.00M $83.19M $-52.18M
2012-12-31 $5.43K $N/A $6.31K $2.03K $4.29K

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 01, 2024 N/A N/A N/A N/A N/A N/A
Jan 29, 2024 N/A N/A N/A N/A N/A N/A
Jan 26, 2024 N/A N/A N/A N/A N/A N/A
Dec 21, 2023 N/A N/A N/A N/A N/A N/A
Oct 16, 2023 N/A N/A N/A N/A N/A N/A
Dec 19, 2022 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist